Yunhe Pharmaceutical (Tianjin) Co., Ltd
Quick facts
Phase 3 pipeline
- INR101 · Cardiovascular
INR101 is an anticoagulant that works by inhibiting the synthesis of vitamin K-dependent clotting factors.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Yunhe Pharmaceutical (Tianjin) Co., Ltd portfolio CI brief
- Yunhe Pharmaceutical (Tianjin) Co., Ltd pipeline updates RSS
Frequently asked questions about Yunhe Pharmaceutical (Tianjin) Co., Ltd
What is Yunhe Pharmaceutical (Tianjin) Co., Ltd's pipeline?
Yunhe Pharmaceutical (Tianjin) Co., Ltd has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include INR101.
Related
- Sector hub: All tracked pharma companies